Skip to main content
Premium Trial:

Request an Annual Quote

Because All They Really Needed Was a Good Argument from a Newsweekly

An article in The Economist makes a case for Europe to get up to speed and embrace GMOs. In the 12 years that genetically modified organisms have been commercially available, both profits and areas under cultivation have grown. What the article doesn't fully address are the reasons that Europeans have pretty much refused to jump on the bandwagon. It sums up: "If future products offer things consumers want, such as healthier food, and address problems that European regulators are worried about, such as obesity and climate change, then GMOs may yet have their day in Europe."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.